Distributing vaccines Down Under
Construction has begun on Toll Group’s new healthcare facility at Tullamarine, near Melbourne to support its partner CSL Seqirus. The 10,000 sqm site will enable quick access to the future CSL Seqirus biotech plant, which, when completed, will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.
Close proximity to this site means that Toll Group can efficiently handle the distribution of finished goods and the supply of raw materials.
Toll also opened a warehouse in Richland, Queensland last year, which was a major expansion of its operations in Australia. With the Tullamarine site set to be operational in August 2024, the company will be looking to enhance its healthcare logistics business in the country. (mk)